Karyopharm Therapeutics (NASDAQ:KPTI) and BioLineRx (NASDAQ:BLRX) Head-To-Head Comparison

BioLineRx (NASDAQ:BLRX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and price targets for BioLineRx and Karyopharm Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1	0	1	1	2.67
Karyopharm Therapeutics	1	0	7	0	2.75

BioLineRx currently has a consensus target price of $26.00, indicating a potential upside of 888.59%. Karyopharm Therapeutics has a consensus target price of $16.71, indicating a potential upside of 112.92%. Given BioLineRx’s higher probable upside, research analysts clearly believe BioLineRx is more favorable than Karyopharm Therapeutics.

Volatility and Risk

BioLineRx has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.

Profitability

This table compares BioLineRx and Karyopharm Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLineRx	-23.38%	-16.11%	-7.20%
Karyopharm Therapeutics	-134.21%	N/A	-122.29%

Valuation & Earnings

This table compares BioLineRx and Karyopharm Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$28.94 million	0.40	-$9.22 million	$0.17	15.47
Karyopharm Therapeutics	$146.07 million	0.99	-$196.04 million	($16.62)	-0.47

BioLineRx has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 1.5% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BioLineRx beats Karyopharm Therapeutics on 8 of the 15 factors compared between the two stocks.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.